Given the supportive role of CD8+ T cells in cancer immunotherapy, a decline in CD8+ T-cell signatures, as found in a cohort of patients with cutaneous metastatic melanoma, whose collective incidence of tumoral BRAF mutations was 21.3%, could independently act as a barrier to immunotherapy [81,82,83,84,85]. The gene discussed is CD8A; the disease is cancer.